Intercept Pharmaceuticals Inc (ICPT) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-5.17 earnings per share for the quarter, missing the analyst consensus estimate by $-1.41. Analysts had a consensus of $-3.76. Analysts expectations of $.64 million. During the same quarter in the previous year, the company posted $-1.78 EPS.
Many Wall Street Analysts have commented on Intercept Pharmaceuticals Inc. Intercept Pharmaceuticals Inc was Downgraded by Morgan Stanley to ” Underweight” on Apr 8, 2016. Intercept Pharmaceuticals Inc was Upgraded by Wells Fargo to ” Outperform” on Apr 5, 2016. Intercept Pharmaceuticals Inc was Initiated by Goldman to “Neutral” on Mar 30, 2016.
Intercept Pharmaceuticals Inc closed down -8.21 points or -5.57% at $139.13 with 3,89,837 shares getting traded on Wednesday. Post opening the session at $146.19, the shares hit an intraday low of $138.8 and an intraday high of $146.38 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on May 4, 2016, Rachel Mcminn (Chief Strategy Officer) sold 130 shares at $147.49 per share price. According to the SEC, on Apr 7, 2016, Mark Pruzanski (CEO & President) sold 708 shares at $130.76 per share price. On Apr 6, 2016, David Shapiro (CMO and EVP – Development) sold 165 shares at $130.76 per share price, according to the Form-4 filing with the securities and exchange commission.
Intercept Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate obeticholic acid (OCA) is a bile acid analog a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.